Trial Profile
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Imiquimod
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms iVAC-CLL01
- 19 Dec 2022 Status changed from completed to discontinued.
- 24 Nov 2022 Status changed from active, no longer recruiting to completed.
- 03 Nov 2022 Status changed from recruiting to active, no longer recruiting.